Cytokinetics Inc (CYTK)

Feb 21, 2025

Cytokinetics (CYTK) Projected to Post Earnings on Tuesday - MarketBeat

Feb 21, 2025

Feb 21, 2025

Allspring Global Investments Holdings LLC Has $4.11 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Feb 21, 2025

Feb 21, 2025

Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Van ECK Associates Corp - MarketBeat

Feb 21, 2025

Feb 20, 2025

Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey

Feb 20, 2025

Feb 20, 2025

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - MSN

Feb 20, 2025

Feb 20, 2025

Insider Sell: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com

Feb 20, 2025

Feb 19, 2025

12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey

Feb 19, 2025

Feb 19, 2025

Fady Ibraham Malik Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat

Feb 19, 2025

Feb 19, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 19, 2025

Feb 19, 2025

Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Peregrine Capital Management LLC - MarketBeat

Feb 19, 2025

Feb 19, 2025

Cytokinetics EVP sells $91,960 in stock By Investing.com - Investing.com South Africa

Feb 19, 2025

Feb 18, 2025

Stifel maintains Buy on Cytokinetics stock, target at $80 By Investing.com - Investing.com Canada

Feb 18, 2025

Feb 18, 2025

Cytokinetics EVP sells $91,960 in stock - Investing.com

Feb 18, 2025

Feb 18, 2025

Cytokinetics (NASDAQ:CYTK) Stock Price Up 7.6%Time to Buy? - MarketBeat

Feb 18, 2025

Feb 17, 2025

Cytokinetics stock touches 52-week low at $41.69 amid market challenges - MSN

Feb 17, 2025

Feb 17, 2025

Cytokinetics (NASDAQ:CYTK) Upgraded by Morgan Stanley to "Overweight" Rating - MarketBeat

Feb 17, 2025

Feb 17, 2025

Cytokinetics jumps amid renewed takeover speculation - MSN

Feb 17, 2025

Feb 16, 2025

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study - MSN

Feb 16, 2025

Feb 16, 2025

Cytokinetics (NASDAQ:CYTK) Reaches New 1-Year LowHere's What Happened - MarketBeat

Feb 16, 2025

Feb 15, 2025

Harvey Capital Management Inc. Acquires Shares of 22,105 Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Feb 15, 2025

Feb 14, 2025

Cytokinetics upgraded by Morgan Stanley on upside potential - MSN

Feb 14, 2025

Feb 13, 2025

Morgan Stanley Upgrades Cytokinetics (CYTK) - MSN

Feb 13, 2025

Feb 13, 2025

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025 - EIN News

Feb 13, 2025

Feb 13, 2025

Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70 - Marketscreener.com

Feb 13, 2025

Feb 13, 2025

This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga

Feb 13, 2025

Feb 13, 2025

Morgan Stanley lifts Cytokinetics stock rating, cuts target to $67 - MSN

Feb 13, 2025

Feb 13, 2025

Morgan Stanley lifts Cytokinetics stock rating, cuts target to $67 By Investing.com - Investing.com UK

Feb 13, 2025

Feb 11, 2025

Cytokinetics adds pharma veteran Landry to board ahead of drug launch - Investing.com Nigeria

Feb 11, 2025

Feb 11, 2025

Cytokinetics' (CYTK) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat

Feb 11, 2025

Feb 11, 2025

Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Citigroup - MarketBeat

Feb 11, 2025

Feb 11, 2025

Cytokinetics Names Robert E. Landry to Board of Directors - GlobeNewswire

Feb 11, 2025

Feb 11, 2025

Cytokinetics adds pharma veteran Landry to board ahead of drug launch By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 11, 2025

Cytokinetics Appoints Robert E. Landry to Board - TipRanks

Feb 11, 2025

Feb 11, 2025

Cytokinetics Names Robert E. Landry To Board Of Directors -February 11, 2025 at 07:53 am EST - Marketscreener.com

Feb 11, 2025

Feb 11, 2025

Cytokinetics Appoints Robert E. Landry to Board of Directors to Enhance Financial and Operational Expertise as Company Prepares for Commercialization - Nasdaq

Feb 11, 2025

Feb 11, 2025

abrdn plc Acquires 102,457 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Feb 11, 2025

Feb 11, 2025

Cytokinetics (NASDAQ:CYTK) Sets New 12-Month LowShould You Sell? - MarketBeat

Feb 11, 2025

Feb 10, 2025

JMP Securities maintains Cytokinetics stock with $78 target - MSN

Feb 10, 2025